Texas, a state with the nation’s most active death penalty, is facing renewed criticism over its opaque process for acquiring lethal injection drugs. Despite a 2015 law designed to protect suppliers’ identities, recent investigations reveal staggering costs—upwards of $775,000 for pentobarbital—and raise serious questions about the ethics, safety, and legality of its procurement methods, including the potential use of expired or improperly sourced compounds.
As Texas approaches a grim milestone of 600 people executed by lethal injection since the early 1980s, the spotlight intensifies on the state’s closely guarded secret: the source of its execution drugs. For a decade, a shield statute passed in 2015 has allowed the Texas Department of Criminal Justice (TDCJ) to conceal the identity of suppliers providing pentobarbital, the sole substance used in lethal injections. However, new revelations are stitching together a cryptic and costly acquisition process, sparking outrage among death penalty critics and raising profound ethical questions.
The High Cost of Secrecy: Millions Spent for Opaque Transactions
Records recently reviewed by NBC News indicate that Texas has procured significant quantities of pentobarbital over the past year. In September 2024, the state acquired 20 1-gram vials, followed by eight 2.5-gram vials in February 2025. This supply is enough for approximately eight executions. While Drug Enforcement Administration forms documenting these purchases redact supplier information, the financial costs paint a stark picture.
A document from the TDCJ, obtained in response to a request for cost information, reveals multiple transactions dated October 2024, and February and March 2025, totaling more than $775,000. This figure far exceeds the wholesale value of pentobarbital. Jeffrey Pilz, an assistant director of pharmacy at The Ohio State University’s Wexner Medical Center, noted that eight 2.5-gram vials of commercially made injectable pentobarbital should cost closer to $20,000. This drastic markup, according to Texas death penalty defense attorney Maurie Levin, raises concerns about the potential purchase of drugs on the black market and the subversion of regulatory channels.
Texas is not alone in this costly pursuit. Other states with similar secrecy laws have also reported shelling out exorbitant sums for execution drugs:
- Idaho spent around $200,000 for three separate purchases of manufactured pentobarbital, with one batch costing more than three times its wholesale price, NBC News previously reported.
- Indiana Governor Mike Braun confirmed his state paid over $1 million for four doses of pentobarbital, some of which expired before use, according to the Indiana Capital Chronicle.
- Utah spent approximately $200,000 for manufactured pentobarbital for a 2024 execution, corrections officials stated.
- Since 2017, Tennessee has purchased nearly $600,000 worth of execution drugs from an undisclosed supplier, as reported by The Tennessean.
Matt Wells, deputy director of Reprieve US, a human rights nonprofit, emphasized that this lack of transparency enables states to avoid publicly revealing steps taken to ensure drug adherence to company protocols and safety. He described the situation as a “system that is broken beyond repair” when states resort to “black market” acquisitions at such immense costs.
The Manufactured vs. Compounded Drug Dilemma
The pharmaceutical industry widely opposes the use of its drugs for capital punishment, leading to a severe shortage for states like Texas. Companies such as Hikma and Sagent, known manufacturers of injectable pentobarbital, have repeatedly asked states not to use their products in executions and have even initiated lawsuits and cease-and-desist letters to prevent such misuse. For instance, Sagent explicitly warned Idaho that diverted products risk being “counterfeit, stolen, contaminated, or otherwise harmful.”
Following a 2015 incident where the FDA seized Texas’s attempted import of sodium thiopental from India, the state reportedly shifted its focus to acquiring pentobarbital from compounding pharmacies within Texas. While manufactured drugs are produced by FDA-approved companies, compounding pharmacies custom-make drugs and are subject to much looser federal scrutiny. This distinction is critical because compounded drugs typically have shorter “beyond use dates” rather than manufacturer-set expiration dates.
A History of Questionable Suppliers and Practices
Texas’s reliance on compounding pharmacies has been fraught with controversy:
- From 2019 to 2023, Rite-Away Pharmacy was identified by an NPR investigation as a supplier, accused by the U.S. Department of Justice of illegally dealing opioids, altering records, and failing to maintain sterile facilities. The pharmacy settled a lawsuit for $275,000. Critics, like Estelle Hebron-Jones of the Texas Defender Service, labeled it a “pill mill” and called for DEA intervention, as detailed by the Austin Chronicle.
- Earlier, a 2018 BuzzFeed News report uncovered that Texas secretly obtained drugs from Green Park Compounding Pharmacy, a facility cited for 48 safety violations, including keeping outdated drugs and improper IV solution preparation. Green Park’s license was on probation after it botched a prescription for children, sending one to the hospital, according to the Death Penalty Information Center.
- In 2013, The Woodlands Compounding Pharmacy was publicly revealed as a supplier after Texas’s previous supply expired, as reported by the Associated Press.
The practice of extending “beyond use dates” on pentobarbital, which Texas has been known to do, is a major point of contention. Death row inmates and opponents have criticized this, questioning whether expired drugs contribute to painful executions. Medical experts, like anesthesiologist Dr. David Waisel, have warned that improper compounding can leave particles in solutions, causing “extraordinary pain” when injected.
The “Use It or Lose It” Conundrum and Legal Battles
Inventory logs reviewed by NBC News indicate that Texas’s pentobarbital stock includes both compounded drugs with “beyond use dates” and manufactured drugs with conventional expiration dates. The eight 2.5-gram vials acquired in February are set to expire at the end of October. This creates a “use it or lose it” scenario for the state, especially when scheduled executions are halted.
This dynamic was starkly illustrated by the case of Robert Roberson, who was scheduled for execution on October 16. Just days before, an appeals court halted his execution, marking the third time his death sentence has been paused. This means the expiring batch of drugs likely cannot be used, as the next execution is not until late January. Maurie Levin criticized this cycle, stating, “The expiration date of illegally purchased drugs should hardly be the engine driving Texas executions.”
The ongoing legal battle over transparency predates the 2015 shield law. In 2014, three death penalty lawyers filed a lawsuit seeking the name of a pharmacy that supplied compounded pentobarbital. While the 2015 law made current suppliers secret, it was not retroactive. Despite repeated losses in lower courts, the Texas Supreme Court initially declined to review a ruling compelling disclosure of the 2014 supplier, then granted a rehearing in a rare reversal, highlighting the state’s fierce commitment to maintaining secrecy, as reported by the Texas Tribune.
The Broader Implications: A System Under Duress
The controversies surrounding Texas’s execution drugs underscore a larger national challenge. As pharmaceutical companies increasingly refuse to supply drugs for capital punishment, states are forced to resort to desperate and often secretive measures. This environment contributes to a higher rate of “botched” executions for lethal injection, as documented by the Death Penalty Information Center, raising concerns about the Eighth Amendment’s prohibition against cruel and unusual punishment.
The persistent calls for transparency, exemplified by State Representative Joe Moody’s repeated efforts to reverse the 2015 secrecy law, highlight the ethical dilemma at the heart of this issue. Moody argues that hiding components of the government’s “ultimate power”—taking a life—undermines public trust and accountability, a sentiment echoed by many who believe citizens have a right to understand the full implications of state-sanctioned executions.
